Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Most loved Fish Dish: What's Your Sea Pleasure? - 2Trying to improve your health and wellness in 2026? Keep it simple
- 3German politician urges more face-to-face interaction in digital age
- 4A Past filled with Old Civilizations: The World's Most established Societies
- 5Nodding off is dangerous. Some animals have evolved extreme ways to sleep in precarious environments
- Farewell, comet 3I/ATLAS! Interstellar visitor heads for the outer solar system after its closest approach to Earth
- Improving as a Cook: Culinary Experiences in the Kitchen
- 7 Peculiar Ways Of starting Your Imagination: Motivation Has Never Been This Good times
- The Most Famous Virtual Entertainment Powerhouses of the Year
- Step by step instructions to Guarantee Your Internet Promoting Degree Supplements Your Profession Objectives
- Examination In progress into Abuse of Japanese Government-Supported Advance
- One dead, six wounded in various crime-related shootings in Israel over the weekend
- Instructions to Back Your Sunlight powered chargers: Tracking down Possible Choices
- Key Little Things That Advantage Old People
